1. Home
  2. ABUS vs PGC Comparison

ABUS vs PGC Comparison

Compare ABUS & PGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABUS
  • PGC
  • Stock Information
  • Founded
  • ABUS 2005
  • PGC 1921
  • Country
  • ABUS United States
  • PGC United States
  • Employees
  • ABUS N/A
  • PGC N/A
  • Industry
  • ABUS Biotechnology: Pharmaceutical Preparations
  • PGC Commercial Banks
  • Sector
  • ABUS Health Care
  • PGC Finance
  • Exchange
  • ABUS Nasdaq
  • PGC Nasdaq
  • Market Cap
  • ABUS 611.0M
  • PGC 536.5M
  • IPO Year
  • ABUS N/A
  • PGC N/A
  • Fundamental
  • Price
  • ABUS $3.22
  • PGC $26.40
  • Analyst Decision
  • ABUS Strong Buy
  • PGC Strong Buy
  • Analyst Count
  • ABUS 4
  • PGC 2
  • Target Price
  • ABUS $5.50
  • PGC $37.00
  • AVG Volume (30 Days)
  • ABUS 774.3K
  • PGC 118.1K
  • Earning Date
  • ABUS 08-04-2025
  • PGC 07-21-2025
  • Dividend Yield
  • ABUS N/A
  • PGC 0.76%
  • EPS Growth
  • ABUS N/A
  • PGC N/A
  • EPS
  • ABUS N/A
  • PGC 1.81
  • Revenue
  • ABUS $6,403,000.00
  • PGC $238,300,000.00
  • Revenue This Year
  • ABUS $3.35
  • PGC $29.32
  • Revenue Next Year
  • ABUS N/A
  • PGC $17.18
  • P/E Ratio
  • ABUS N/A
  • PGC $14.58
  • Revenue Growth
  • ABUS N/A
  • PGC 16.62
  • 52 Week Low
  • ABUS $2.71
  • PGC $23.96
  • 52 Week High
  • ABUS $4.73
  • PGC $37.88
  • Technical
  • Relative Strength Index (RSI)
  • ABUS 48.90
  • PGC 36.27
  • Support Level
  • ABUS $3.08
  • PGC $25.50
  • Resistance Level
  • ABUS $3.30
  • PGC $30.28
  • Average True Range (ATR)
  • ABUS 0.10
  • PGC 0.97
  • MACD
  • ABUS 0.01
  • PGC -0.50
  • Stochastic Oscillator
  • ABUS 50.00
  • PGC 17.08

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

About PGC Peapack-Gladstone Financial Corporation

Peapack Gladstone Financial Corp provides banking services. It operates through two segments namely Banking, which involves the delivery of loans and deposits, and Wealth Management Division which includes asset management services. The banking segment includes commercial real estate, multifamily, residential and consumer lending, deposit generation, and Internet banking services. Wealth Management includes investment management services for individuals and institutions; personal trust services, administrator, custodian and guardians, and other financial planning and advisory services. The services provided by the company include checking and savings accounts, money market and interest-bearing checking accounts, certificates of deposit, individual retirement accounts, and other services.

Share on Social Networks: